RecruitingNot ApplicableNCT03675412
Caffeine Consumption in Glaucoma Patients and Healthy Subjects
Acute Changes in Optic Nerve Head (ONH) and Macular Blood Flow After Caffeine Consumption in Glaucoma Patients and Healthy Subjects: A Quantitative Optic Coherence Tomography Angiography (OCTA) Study
Sponsor
Wills Eye
Enrollment
80 participants
Start Date
Dec 30, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria3
- age 18 to 90 years
- diagnosis of primary open angle glaucoma (Mild, Moderate and Advanced)
- healthy subjects with no eye disease
Exclusion Criteria15
- Diseases, ophthalmic or systemic, that are likely to affect OCTA results
- greater than moderate cataract
- nystagmus
- inability to look at target
- macular degeneration other than mild drusen or pigmentary changes
- diabetic retinopathy
- neovascular glaucoma or non-glaucoma optic neuropathies
- current macular edema, prior laser to retina, inflammatory retinopathy or choroidopathy
- keratoconus, corneal ectasia, central corneal scarring
- rheumatologic diseases or Raynaud's phenomena
- pregnant and lactating women
- mental illness or alcohol addiction
- pre-existing bladder symptoms, cardiac disease or sleep disorder
- refractive spherical diopter greater than 5 or cylinder greater than 3
- possible tolerance to caffeine (drinking more than 1 cup coffee per day).
Interventions
DIETARY_SUPPLEMENTCaffeine tablet
Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03675412